Planet Labs Stock Is Down 67% From Its High. Time To Buy?

Planet Labs shares have fallen about 67% from their May peak, pressured by a $1.5 billion equity-dilution program and cautious Q3 revenue guidance. First-half fiscal 2027 revenue nevertheless rose 44% year over year to $210 million, while the company generated more than $21 million in free cash flow despite a reported $148 million loss, including a $106 million non-cash warrant-liability fair-value impact. Its price-to-sales multiple has declined from a June peak of 49x to roughly 15x; analysts project revenue growth of 42% this fiscal year and 31% in fiscal 2028, supporting a cautious dollar-cost-averaging investment case.

Analysis

PL's investability hinges less on imagery uniqueness than on whether recurring government demand converts into durable gross-margin expansion and self-funded constellation replacement. The equity-raise overhang changes the valuation framework: even if revenue compounds near current estimates, per-share upside is capped until management establishes a credible ceiling on capital needs, dilution cadence, and satellite replenishment spend. A 15x sales multiple remains vulnerable because the market will capitalize PL as a capital-intensive data provider, not as a software platform, unless operating leverage becomes visible.

Near term (days to weeks), continued selling can be self-reinforcing: small-cap growth holders facing losses and uncertain float expansion have little incentive to add before the next guidance reset. Over 1-3 months, the relevant catalyst is not headline contract wins but backlog duration, net retention, remaining performance obligations, and FCF after constellation capex; a beat without an improved FY28 margin/FCF trajectory is unlikely to rerate the shares. The key falsifier for a tactical long is another guidance reduction or an equity issuance before a material improvement in contracted revenue visibility.

The non-obvious beneficiary of PL's funding pressure is BlackSky (BKSY), whose differentiated high-resolution, taskable imagery could gain procurement share if agencies diversify vendors rather than depend on one daily-monitoring provider. Conversely, a broad defense/intelligence budget slowdown would hit both names, while better-funded primes such as RTX and LMT can absorb Earth-observation capabilities within much larger contract portfolios. Consensus may be overemphasizing the reported non-cash loss, but it may also be underestimating the recurring cash cost of maintaining a technological lead in a rapidly depreciating satellite fleet.

Key Decisions for Investors

• No immediate directional PL purchase while the equity-program utilization, cash balance, and FY28 capex plan remain undisclosed; set an alert for the next earnings release and require unchanged/raised revenue guidance plus positive FCF after constellation investment before initiating.
• For a 1-3 month tactical setup, consider a small PL long only after a base forms above the post-guidance low and management quantifies dilution; target a rerating toward 18-20x forward sales if backlog and FCF metrics improve, with a stop on a close below the new base or any incremental capital raise.
• Express relative imagery demand through long BKSY / short PL only if PL's next update confirms further financing needs while BKSY demonstrates contract-booking momentum; size modestly given liquidity and shared government-budget exposure, and exit if PL secures multiyear awards that materially extend revenue visibility.
• Avoid using NVDA or NFLX as read-through trades: neither has a direct earnings sensitivity to PL's funding, procurement, or satellite-economics debate.